Dr. Reddy’s Laboratories Faces Securities Investigation After Earnings Miss

The scrutiny centers on a substantial discrepancy highlighted by Chief Financial Officer M.V. Narasimham on May 12, 2026. During an investor call, Narasimham touted an adjusted profit before tax of INR 994 crores, while the reported figure stood at just INR 199 crores—a gap of nearly INR 800 crores. This presentation of adjusted EBITDA margins is now being weighed against the company’s July 22 disclosure of a ₹2.4 billion provision linked to defective semaglutide batches.

Investors who incurred losses following the subsequent 9% drop in share price are being urged to provide trading records to determine eligibility for potential litigation. The investigation, spearheaded by Levi & Korsinsky LLP, aims to clarify if the company’s reliance on non-GAAP metrics obscured underlying financial risks prior to the recent earnings miss.